You just read:

SiteOne Therapeutics Announces Research and Development Agreement With Amgen to Advance Portfolio of Highly Selective, Potent Inhibitors of NaV1.7 for Acute and Chronic Pain

News provided by

SiteOne Therapeutics

Jan 06, 2017, 09:00 ET